Affordable Access

Publisher Website

Imaging of the glioma microenvironment by TSPO PET.

  • Zinnhardt, Bastian1, 2
  • Roncaroli, Federico3, 4
  • Foray, Claudia1
  • Agushi, Erjon3, 4
  • Osrah, Bahiya3, 4
  • Hugon, Gaëlle5
  • Jacobs, Andreas H1, 6
  • Winkeler, Alexandra7, 8
  • 1 European Institute for Molecular Imaging (EIMI), Westfälische Wilhelms-University Münster (WWU), Münster, Germany. , (Germany)
  • 2 Biomarkers and Translational Technologies, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. , (Switzerland)
  • 3 Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Manchester, UK.
  • 4 Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Brain and Mental Health, University of Manchester, Manchester, UK.
  • 5 Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Université Paris-Saclay, Orsay, France. , (France)
  • 6 Department of Geriatrics and Neurology, Johanniter Hospital, Bonn, Germany. , (Germany)
  • 7 Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Université Paris-Saclay, Orsay, France. [email protected] , (France)
  • 8 CEA, DRF, JOLIOT, SHFJ, Orsay, France. [email protected] , (France)
Published Article
European Journal of Nuclear Medicine
Publication Date
Mar 15, 2021
DOI: 10.1007/s00259-021-05276-5
PMID: 33721063


Gliomas are highly dynamic and heterogeneous tumours of the central nervous system (CNS). They constitute the most common neoplasm of the CNS and the second most common cause of death from intracranial disease after stroke. The advances in detailing the genetic profile of paediatric and adult gliomas along with the progress in MRI and PET multimodal molecular imaging technologies have greatly improved prognostic stratification of patients with glioma and informed on treatment decisions. Amino acid PET has already gained broad clinical application in the study of gliomas. PET imaging targeting the translocator protein (TSPO) has recently been applied to decipher the heterogeneity and dynamics of the tumour microenvironment (TME) and its various cellular components especially in view of targeted immune therapies with the goal to delineate pro- and anti-glioma immune cell modulation. The current review provides a comprehensive overview on the historical developments of TSPO PET for gliomas and summarizes the most relevant experimental and clinical data with regard to the assessment and quantification of various cellular components with the TME of gliomas by in vivo TSPO PET imaging.

Report this publication


Seen <100 times